Clotrimazole Bionika Pregnancy

• Pregnancy of Clotrimazole Bionika in details
• Clotrimazole Bionika breastfeeding
• Clotrimazole Bionika reviews

Pregnancy of Clotrimazole Bionika in details

Pregnancy predisposes patients to the development of vaginal candidiasis due to changes in the vaginal tract. Clotrimazole Bionika has been used in several clinical trials for the treatment of vaginal candidiasis during the second and third trimester without evidence of fetal harm. One trial included 57 patients in their first trimester. Again no adverse effects were attributed to Clotrimazole Bionika. In a review of 229,101 deliveries to Michigan Medicaid patients, 2624 first-trimester exposures to Clotrimazole Bionika and 8590 exposures any time during pregnancy were recorded. A total of 118 birth defects were reported with first trimester exposure (112 expected) and included (observed/expected) 27/26 cardiovascular defects, 3/1 spina bifida, 4/4 oral clefts, 9/6 polydactyly, 1 limb reduction, and 6/6 hypospadias. (written communication, Franz Rosa, MD, Food and Drug Administration, 1994) These data do not support an association between first-trimester Clotrimazole Bionika use and birth defects.

Clotrimazole Bionika has been assigned to pregnancy category C by the FDA when given as oral troches, and pregnancy category B when used intravaginally or topically. Animals given high doses intravaginally and orally have not shown evidence of teratogenicity. In clinical trials involving women in their second and third trimester, Clotrimazole Bionika treatment of vaginal candidiasis has not been associated with fetal harm. Clotrimazole Bionika use has not been well studied during the first trimester. Clotrimazole Bionika is only recommended for use during pregnancy when benefit outweighs risk.

Clotrimazole Bionika breastfeeding

There are no data on the excretion of Clotrimazole Bionika into human milk.

See references

References for pregnancy information

1. "Product Information. Mycelex (Clotrimazole Bionika)." Bayer, West Haven, CT.
2. Haram K, Digranes A "Vulvovaginal candidiasis in pregnancy treated with Clotrimazole Bionika." Acta Obstet Gynecol Scand 57 (1978): 453-5
3. Frerich W, Gad A "The frequency of Candida infections in pregnancy and their treatment with Clotrimazole Bionika." Curr Med Res Opin 4 (1977): 640-4
4. Tan CG, Good CS, Milne LJ, Loudon JD "A comparative trial of six day therapy with Clotrimazole Bionika and nystatin in pregnant patients with vaginal candidiasis." Postgrad Med J 50 Suppl 1 (1974): 102-5
5. Lindeque BG, van Niekerk WA "Treatment of vaginal candidiasis in pregnancy with a single Clotrimazole Bionika 500 mg vaginal pessary." S Afr Med J 65 (1984): 123-4

References for breastfeeding information

1. "Product Information. Mycelex (Clotrimazole Bionika)." Bayer, West Haven, CT.

References

1. DailyMed. "BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
2. PubMed Health. "Mycelex: This section provide the link out information of drugs collectetd in PubMed Health. ". http://www.ncbi.nlm.nih.gov/pubmedhe... (accessed September 17, 2018).
3. Human Metabolome Database (HMDB). "Clotrimazole: The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body.". http://www.hmdb.ca/metabolites/HMDB0... (accessed September 17, 2018).

Reviews

Consumer reviews

Information checked by Dr. Sachin Kumar, MD Pharmacology